Wu Q, Manning M, Schmidt-Ullrich R, Mohan R
Department of Radiation Oncology, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298, USA.
Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):195-205. doi: 10.1016/s0360-3016(99)00304-1.
Conventional radiotherapy for cancers of the head and neck (HN) can yield acceptable locoregional tumor control rates, but toxicity of many normal tissues limits our ability to escalate dose. Xerostomia represents one of the most common complications. The purpose of this study is to investigate the potential of intensity-modulated radiotherapy (IMRT) to achieve adequate sparing of parotids and to escalate nominal and/or biologically-effective dose to achieve higher tumor control without exceeding normal tissue tolerances.
An IMRT optimization system, developed at our institution for research and clinical purposes, and coupled to a commercial radiation treatment planning system, has been applied to a number of cases of HN carcinomas. IMRT plans were designed using dose- and dose-volume-based criteria for 4 and 6 MV coplanar but non-collinear beams ranging in number from 5 to 15 placed at equi-angular steps. Detailed analysis of one of the cases is presented, while the results of the other cases are summarized. For the first case, the IMRT plans are compared with the standard 3D conformal radiation treatment (3DCRT) plan actually used to treat the patient, and with each other. The aim of the 3DCRT plan for this particular case was to deliver 73 Gy to the tumor volume in 5 fractions of 2 Gy and 28 fractions of 2.25 Gy/fx; and 46 Gy to the nodes in 2 Gy/fx while maintaining critical normal tissues to below specified tolerances. The IMRT plans were designed to be delivered as a "simultaneous integrated boost" (SIB) using the "sweeping window" technique with a dynamic MLC. The simultaneous integrated boost strategy was chosen, partly for reasons of efficiency in planning and delivery of IMRT treatments, and partly with the assumption that dose distributions in such treatments are more conformal and spare normal tissues to a greater extent than those with sequential boost strategy. Biologically equivalent dose normalized to 2 Gy/fx, termed here as normalized total dose (NTD), for this strategy was calculated using published head and neck fractionation data.
IMRT plans were more conformal than the 3DCRT plans. For equivalent coverage of the tumor and the nodes, and for the dose to the spinal cord and the brainstem maintained within tolerance limits, the dose to parotids was greatly reduced. For the detailed example presented, it was shown that the tumor and the nodes in the 3DCRT plan receive NTDs of 78 and 46 Gy, respectively. For the IMRT plan, a nominal dose of 70 Gy could be delivered to the tumor in 28 fractions of 2.5 Gy each, simultaneously with 50.4 Gy to nodes with 1.8 Gy/fx. The two are biologically equivalent to 82 and 46 Gy, respectively, if delivered in 2 Gy/fx. Similar computations were carried out for other cases as well. The quality of IMRT plans was found to improve with increasing number of beams, up to 9 beams. Dose-volume-based criteria led to a modest improvement in IMRT plans and required less trial and error.
IMRT has the potential to significantly improve radiotherapy of HN cancers by reducing normal tissue dose and simultaneously allowing escalation of dose. SIB strategy is not only more efficient and yields better dose distributions, but may also be biologically more effective. Dose-volume-based criteria is better than purely dose-based criteria. The quality of plans improves with number of beams, reaching a saturation level for a certain number of beams, which for the plans studied was found to be 9.
头颈部(HN)癌的传统放射治疗可产生可接受的局部区域肿瘤控制率,但许多正常组织的毒性限制了我们增加剂量的能力。口干是最常见的并发症之一。本研究的目的是探讨调强放射治疗(IMRT)在充分保护腮腺方面的潜力,并增加标称剂量和/或生物有效剂量,以在不超过正常组织耐受量的情况下实现更高的肿瘤控制。
我们机构开发的用于研究和临床目的的IMRT优化系统,与商业放射治疗计划系统相结合,已应用于多例HN癌病例。IMRT计划使用基于剂量和剂量体积的标准进行设计,用于4和6MV共面但非共线的射束,射束数量从5到15不等,以等角步长放置。给出了其中一个病例的详细分析,同时总结了其他病例的结果。对于第一个病例,将IMRT计划与实际用于治疗该患者的标准三维适形放射治疗(3DCRT)计划以及相互之间进行比较。该特定病例的3DCRT计划的目标是在5次2Gy分割和28次2.25Gy/分割中向肿瘤体积给予73Gy;并在2Gy/分割中向淋巴结给予46Gy,同时将关键正常组织保持在规定耐受量以下。IMRT计划设计为使用动态多叶准直器的“扫描窗口”技术以“同步整合推量”(SIB)方式进行。选择同步整合推量策略,部分原因是IMRT治疗计划和实施的效率,部分原因是假设这种治疗中的剂量分布比序贯推量策略的剂量分布更适形且能更大程度地保护正常组织。使用已发表的头颈部分割数据计算该策略的归一化为2Gy/分割的生物等效剂量,在此称为归一化总剂量(NTD)。
IMRT计划比3DCRT计划更适形。对于肿瘤和淋巴结的等效覆盖,以及脊髓和脑干的剂量保持在耐受限度内,腮腺的剂量大幅降低。对于所呈现的详细示例,显示3DCRT计划中的肿瘤和淋巴结分别接受78和46Gy的NTD。对于IMRT计划,可以在28次每次2.5Gy中向肿瘤给予标称剂量70Gy,同时向淋巴结给予1.8Gy/分割的50.4Gy。如果以2Gy/分割给予,两者的生物等效剂量分别为82和46Gy。对其他病例也进行了类似计算。发现IMRT计划的质量随着射束数量增加而提高,直至9束射束。基于剂量体积的标准使IMRT计划有适度改善,并且需要的试错更少。
IMRT有潜力通过降低正常组织剂量并同时允许增加剂量来显著改善HN癌的放射治疗。SIB策略不仅更高效且产生更好的剂量分布,而且在生物学上可能也更有效。基于剂量体积的标准优于纯粹基于剂量的标准。计划质量随着射束数量提高,对于所研究的计划,在一定数量的射束时达到饱和水平,发现该数量为9束。